Dalteparin, a Low Molecular Weight Heparin, as Part of Combination Therapy for Patients with Kawasaki Disease: a Retrospective and Pilot Study

Dalteparin, a Low Molecular Weight Heparin, as Part of Combination Therapy for Patients with Kawasaki Disease: a Retrospective and Pilot Study - Dalteparin in combination therapy for KD

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010349

Enrollment

238

Registered

2013-03-29

Start date

2004-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kawasaki disease

Interventions

This retrospective study comprised two parts. Subjects with Kawasaki disease (KD) (n = 126), admitted from January 2004 to June 2008, received either dalteparin at 75 IU/kg/h, IVIG at 400 mg/kg/d for

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The diagnostic criteria are compliant with the Diagnostic Guidelines for Kawasaki Disease (5th revision).

Exclusion criteria

Exclusion criteria: Patients presenting with CAL before the initial treatment were also excluded from the study.

Design outcomes

Primary

Measure	Time frame
A survey of coronary artery lesion (CAL), resistance for intravenous immunoglobulin (IVIG) therapy and additional IVIG therapy was performed within one months of all patients.	—

Secondary

Measure	Time frame
A survey of cardiac sequelae was performed using echocardiography at follow-up, within three months of discharge of all patients.	—

Countries

Japan

Contacts

Public ContactYasuji Inamo

Nihon University School of Medicine Department of pediatrics and child health

inamo.yasuji@nihon-u.ac.jp03-3972-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026